Novartis' chronic lung disease drug wins approval in EU, Japan

09/25/2013 | PharmaTimes (U.K.)

Novartis obtained approval from the European Commission to market its once-daily Ultibro Breezhaler, or QVA149, as a maintenance therapy for chronic obstructive pulmonary disease. The Japanese Ministry of Health, Labour and Welfare approved Ultibro Inhalation Capsules, delivered using the Breezhaler device, to treat symptoms of COPD.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI